Ribonoscopy and “Theragnostics” - Molecular Theory of the Living Cell - page 599

Fig. 19.2 Ribonic spectra of normal human cancer cells, and cancer cells isolated from human
breast tissues “before” or “after” treating with doxorubicin for ~16 weeks (n 54) (Perou et al.

2000) (I thank Drs. J.K. Lee and J.K. Eom for their assistance in producing these graphs)

¼

Table 19.2 The definitions of the cancer-related and drug-responding RNAs
RNA levels
Cancer-related Drug-responding

Positively Negatively Positively Negatively

BE > NO BE < NO BE > AF > NO e.g., AF > BE > NO

BE < AF < NO e.g., BE < NO < AF

We may refer to this statement as the “ribons-as-cell-state-biomarkers”
(RACSB) hypothesis, which is evidently consistent with the more general IDS-
Cell Function Identity Hypothesis discussed in Sect. 10.2 .
As indicated in Fig. 19.2 , the 90% of the 54 energy-metabolizing RNAs
exhibited concentration levels that are different for each one of the three human
breast tissues - Normal, BE, and AF. Based on the “ribons-as-cell-state-
biomarkers” hypothesis, it should be possible to identify those RNA molecules
whose levels are affected by tumors before or after drug therapy. We will arbitrarily
define the RNA “positively cancer-related” as the RNAs whose levels in tumor
before drug therapy (BE) is higher than in normal tissues (NO), i.e., BE

NO (see
the first column in Table 19.2 ). Any RNA molecules whose levels are lower in
tumors than in normal tissues are then defined as “negatively cancer-related” (see
the second column in Table 19.2 ). We can recognize two kinds of drug-responding
RNAs - (1) positively drug-responding RNAs, if their levels in tumor after (AF)
drug therapy are “sandwiched” between their levels in normal (NO) and tumor

>